Carbidopa/levodopa (WD-1603) vs Levodopa (Inbrija)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline
Carbidopa/levodopa (WD-1603)
Developed by Hong Kong WD Pharmaceutical Co., Limited
NCT05036473 · Phase 2 · completed
This randomized, double-blind, placebo-controlled Phase 2 trial in early Parkinson's disease enrolled only 40 patients across three dose groups and placebo. All three doses of WD-1603 produced a statistically significant improvement in combined motor and daily-living function scores versus placebo at 27 days, with the largest effect at the highest dose (p=0.0003), but the very small sample size means these results need confirmation in a larger trial.
Reported efficacy
To compare the changes from the baseline mean value before the study to the mean value on the 27th day of the study between each dose group and the placebo group. (27 days- from the baseline to the 27th day): Day 27 MDS-UPDRS II+III total score, LS mean change from baseline vs placebo: low dose -6.7 (p=0.0388); medium dose -8.5 (p=0.0125); high dose -13.6 (p=0.0003) (met)
Result source: NCT05036473
Levodopa (Inbrija)
Marketed by Merz Therapeutics and partners
NCT02240030 · Phase 3 · completed
This randomized, double-blind, placebo-controlled phase 3 trial assigned 351 participants to CVT-301 60 mg, CVT-301 84 mg or placebo. Its clinical primary endpoint, the change in UPDRS motor score from predose to 30 minutes post-dose at week 12 for 84 mg versus placebo, was met: -9.83 versus -5.91, a difference of -3.92 points (95% CI -6.84 to -1.00; p=0.0088), as reported in the peer-reviewed publication.
Reported efficacy
Unified Parkinson's Disease Rating Scale (UPDRS) Part III (30 minutes post-dose at week 12): UPDRS motor score change, predose to 30 min post-dose at week 12: CVT-301 84 mg -9.83 vs placebo -5.91; difference -3.92 (95% CI -6.84 to -1.00), p=0.0088 (LeWitt et al., Lancet Neurol 2019) (met)
Result source: NCT02240030
Results for Parkinson's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
| Key endpoint | Carbidopa/levodopa (WD-1603) | Levodopa (Inbrija) |
|---|---|---|
| OFF time, change | —Not reported | —Not reported |
| ON time without troublesome dyskinesia, change | —Not reported | —Not reported |
| UPDRS Part III, change | —Not reported | -9.8 vs -5.9−3.9 vs placeboNCT022400304 other results
|
| MDS-UPDRS Part II, change | —Not reported | —Not reported |
OFF time, change
- Carbidopa/levodopa (WD-1603)
- —Not reported
- Levodopa (Inbrija)
- —Not reported
ON time without troublesome dyskinesia, change
- Carbidopa/levodopa (WD-1603)
- —Not reported
- Levodopa (Inbrija)
- —Not reported
UPDRS Part III, change
- Carbidopa/levodopa (WD-1603)
- —Not reported
- Levodopa (Inbrija)
- -9.8 vs -5.9−3.9 vs placeboNCT02240030
4 other results
- -8.5 vs -6.5 NCT02240030
- -9.0 vs -6.5 NCT02240030
- -5.2 vs -4.2 NCT02240030
- -6.5 vs -4.2 NCT02240030
MDS-UPDRS Part II, change
- Carbidopa/levodopa (WD-1603)
- —Not reported
- Levodopa (Inbrija)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Carbidopa/levodopa (WD-1603): 0 of 4 rows · Levodopa (Inbrija): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Carbidopa/levodopa (WD-1603) | Levodopa (Inbrija) |
|---|---|---|
| Dropout rate | — | 14.9%CVT-301 High Dosea NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 show 4 more results15%CVT-301 Low Dose NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 28.7%HIgh Dose NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 38.5%Low Dose NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 2.5% NCT02352363 · Phase 3 · monotherapy |
| Discontinued due to AEs | — | —CVT-301 High Dosea NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 show 4 more results—CVT-301 Low Dose NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 9.1%HIgh Dose NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 8.1%Low Dose NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 — NCT02352363 · Phase 3 · monotherapy |
| Serious AEs | — | 1.8%CVT-301 High Dosea NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 show 4 more results5.3%CVT-301 Low Dose NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 8.2%HIgh Dose NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 14.4%Low Dose NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 15.5% NCT02352363 · Phase 3 · monotherapy |
| Most frequent reported AEs | — | a cough 14.9% (placebo 1.8%) upper respiratory tract 6.1% (placebo 2.7%) nausea 5.3% (placebo 2.7%) NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 show 4 more resultscough 15% (placebo 1.8%) throat irritation 7.1% (placebo 0%) dyskinesia 4.4% (placebo 0%) NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 HIgh Dose cough 14.5% fall 10.7% upper respiratory tract infection 7.5% NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 Low Dose cough 16.3% fall 15.7% upper respiratory tract infection 6.5% NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 |
Notes
- aPopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Carbidopa/levodopa (WD-1603)
show 2 more results
Levodopa (Inbrija)
show 4 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Carbidopa/levodopa (WD-1603)'s landscape · Levodopa (Inbrija)'s landscape